Summit Therapeutics said Sunday that the FDA rejected ivonescimab, a lung cancer treatment it developed with Chinese drugmaker Akeso. In a letter to the companies, regulators said the drug could not be approved because it did not help patients live longer; although it slowed worsening, the absence o